What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?

Basit Öğe Kaydı
dc.contributor.authorAbdulmajed, Mohamed Ismat
dc.contributor.authorSancak, Eyup Burak
dc.contributor.authorResorlu, Berkan
dc.contributor.authorAl-Chalaby, Gydhia Zuhair
dc.date.accessioned2025-01-27T21:21:16Z
dc.date.available2025-01-27T21:21:16Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractUrothelial carcinoma is the 9th most common cancer worldwide. Most urothelial tumors are non-muscle invasive on presentation. However, two-thirds of non-invasive bladder cancers will eventually recur with a 25% risk of progression to muscle-invasive bladder cancer. Tumor stage, histological grade and pathological invasion of blood vessels and lymphatic tissue are the main indicators for urothelial cancer prognosis. The gold standard for diagnosing bladder cancer is conventional white-light cystoscopy and biopsy. Urine cytology is a highly specific, sensitive test for high-grade tumors or carcinoma in situ (CIS). Urinary NMP22 has an overall sensitivity and specificity for detecting bladder cancer of 49% and 87%, respectively. However, there are false-positive results in the presence of urinary tract infection or hematuria. The detection of specific gene mutations related to urothelial cancers has been studied and employed to reproduce markers helpful for diagnosis. According to current studies, molecular markers can be used to predict tumor recurrence. From a prognostic point of view, new molecular markers have yet to be established as reliable indicators of tumor aggressiveness. We aimed to review the molecular markers with possible prognostic significance that have been discussed in the literature. This review examined the literature for various molecular markers under development for bladder cancer in an attempt to optimize patient care and reduce the costs of treating these patients.
dc.identifier.doi10.5152/tud.2014.60973
dc.identifier.endpage232
dc.identifier.issn2149-3235
dc.identifier.issn2149-3057
dc.identifier.issue4
dc.identifier.pmid26328183
dc.identifier.scopus2-s2.0-84916607237
dc.identifier.scopusqualityN/A
dc.identifier.startpage228
dc.identifier.trdizinid165072
dc.identifier.urihttps://doi.org/10.5152/tud.2014.60973
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/165072
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28867
dc.identifier.volume40
dc.identifier.wosWOS:000420589000007
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAves
dc.relation.ispartofTurkish Journal of Urology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectBladder cancer
dc.subjectmolecular markers
dc.subjectpredictor of tumor recurrence
dc.titleWhat are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu